MAZE vs MBX

Maze Therapeutics, Inc. vs MBX Biosciences, Inc. — Valuation Comparison 2026

MAZE

Biotechnology
Maze Therapeutics, Inc.
Quality
5.4
out of 10
Value Trap
Price
$26.40
Last close
Models
9/13
Active
VS

MBX

Biotechnology
MBX Biosciences, Inc.
Quality
4.5
out of 10
Value Trap
12
SAFE
Price
$31.90
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType MAZE Fair ValueMAZE Upside MBX Fair ValueMBX Upside
Bayesian DCF Intrinsic $3.40 -87.1% $9.00 -71.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $7.76 -71.4% $6.36 -80.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MAZE vs MBX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MAZE vs MBX — Which Stock Is More Undervalued?

MAZE scores higher with a 5.4/10 quality rating vs MBX's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Maze Therapeutics, Inc. (MAZE) and MBX Biosciences, Inc. (MBX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MAZE currently trades at $26.40 with a QOC of 5.4/10, while MBX trades at $31.90 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).